The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Prednisone in Duchenne Dystrophy: A Randomized, Controlled Trial Defining the Time Course and Dose Response
Abstract
A randomized, controlled trial of daily prednisone was conducted in 99 boys (aged 5 to 15 years) with Duchenne dystrophy to define the time course of improvement and the dose response to treatment. Prednisone at 0.3 mg/kg (n = 33), prednisone at 0.75 mg/kg (n = 34), and placebo (n = 32) were administered for 6 months. Patients were examined using manual muscle and myometry testing, timed functional testing, pulmonary function testing, and laboratory measurements at 10 days, 1 month, 2 months, 3 months, and 6 months of treatment. Boys treated with prednisone had stronger average muscle strength scores, than did boys treated with placebo as early as 10 days after starting therapy. At the 3-month visit, the boys in the group given 0.75 mg/kg of prednisone were significantly stronger than those in the group given 0.3 mg/kg of prednisone, indicating a dose response. At 6 months, significant side effects occurred in the group treated with 0.75 mg/kg of prednisone, including weight gain, cushingoid appearance, and excessive hari growth. Only weight gain was observed in the group taking prednisone at a dose of 0.3 mg/kg. Importantly, no side effects were evident at 10 days or 1 month of treatment, despite improvement in muscle strength and function. We conclude that prednisone produces a rapid increase in muscle strength in patients with Duchenne dystrophy and that this improvement is maximal at a prednisone dosage of 0.75 mg/kg or less.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Direct Gene Transfer into Mouse Muscle in Vivo
Wolff, J. A., Malone, R. W., Williams, P., Chong, W., Acsadi, G., Jani, A., & Felgner, P. L. (1990) · Science · doi:10.1126/science.1690918 · Cited by 4,173
The complete sequence of dystrophin predicts a rod-shaped cytoskeletal protein
Koenig, M., Monaco, A. P., & Kunkel, L. M. (1988) · Cell · doi:10.1016/0092-8674(88)90383-2 · Cited by 1,538
Conversion of mdx myofibres from dystrophin-negative to -positive by injection of normal myoblasts
Partridge, T. A., Morgan, J. E., Coulton, G. R., Hoffman, E. P., & Kunkel, L. M. (1989) · Nature · doi:10.1038/337176a0 · Cited by 878
Arahata, K., & Engel, A. G. (1984) · Annals of Neurology · doi:10.1002/ana.410160206 · Cited by 630
Clinical trial in duchenne dystrophy. I. The design of the protocol
Brooke, M. H., Griggs, R. C., Mendell, J. R., Fenichel, G. M., Shumate, J. B., & Pellegrino, R. J. (1981) · Muscle & Nerve · doi:10.1002/mus.880040304 · Cited by 564
Self-citationRandomized, Double-Blind Six-Month Trial of Prednisone in Duchenne's Muscular Dystrophy
Mendell, J. R., Moxley, R. T., Griggs, R. C., Brooke, M. H., Fenichel, G. M., Miller, J. P., King, W., Signore, L., Pandya, S., Florence, J., et al. (1989) · New England Journal of Medicine · doi:10.1056/nejm198906153202405 · Cited by 520
Self-citationDuchenne muscular dystrophy: Patterns of clinical progression and effects of supportive therapy
Brooke, M. H., Fenichel, G. M., Griggs, R. C., Mendell, J. R., Moxley, R., Florence, J., King, W. M., Pandya, S., Robison, J., Schierbecker, J., et al. (1989) · Neurology · doi:10.1212/wnl.39.4.475 · Cited by 353
Self-citationBrooke, M. H., Fenichel, G. M., Griggs, R. C., Mendell, J. R., Moxley, R., Miller, J. P., & Province, M. A. (1983) · Muscle & Nerve · doi:10.1002/mus.880060204 · Cited by 353
Self-citationPREDNISONE IN DUCHENNE MUSCULAR DYSTROPHY
Drachman, D. B., Toyka, K. V., & Myer, E. (1974) · The Lancet · doi:10.1016/s0140-6736(74)90071-3 · Cited by 212
Papillary renal cell carcinoma. A morphologic and cytogenetic study of 11 cases.
Kovács, G. (1989) · PubMed · Cited by 177
Cited by
Bushby, K., Finkel, R., Birnkrant, D. J., Case, L. E., Clemens, P. R., Cripe, L., Kaul, A., Kinnett, K., McDonald, C., Pandya, S., et al. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70271-6 · Cited by 2,053
Respiratory Care of the Patient with Duchenne Muscular Dystrophy: ATS Consensus Statement
(2004) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200307-885st · Cited by 733
Corticosteroids for the treatment of Duchenne muscular dystrophy
Matthews, E., Brassington, R., Kuntzer, T., Jichi, F., & Manzur, A. Y. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003725.pub4 · Cited by 493
Glucocorticoid corticosteroids for Duchenne muscular dystrophy
Manzur, A. Y., Kuntzer, T., Pike, M., & Swan, A. V. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003725.pub3 · Cited by 437
Ataluren treatment of patients with nonsense mutation dystrophinopathy
Bushby, K., Finkel, R., Wong, B., Barohn, R., Campbell, C., Comi, G. P., Connolly, A. M., Day, J. W., Flanigan, K. M., Goemans, N., et al. (2014) · Muscle & Nerve · doi:10.1002/mus.24332 · Cited by 428
Metadata
- Authors
- Griggs, R. C.
- Venue
- Archives of Neurology
- Publisher
- American Medical Association (AMA)
- Published
- 1991-04-01
- Volume
- 48
- Issue
- 4
- Pages
- 383
- ISSN
- 0003-9942 (ISSN-L)
- OpenAlex
- W2016615191
- Cited by
- 279
- References
- 15
- FWCI
- 1.90
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Prednisone in Duchenne Dystrophy: A Randomized, Controlled Trial Defining the Time Course and Dose Response. https://app.cochat.ai/papers/10.1001/archneur.1991.00530160047012
- The paper
- Griggs, R. C. (1991). Prednisone in Duchenne Dystrophy: A Randomized, Controlled Trial Defining the Time Course and Dose Response. Archives of Neurology. https://doi.org/10.1001/archneur.1991.00530160047012
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.